Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

Y-mAbs Therapeutics (YMAB) announced the presentation of a trial in progress poster on GD2-SADA pretargeted radioimmunotherapy (PRIT) at the Advances in Neuroblastoma Research Meeting. Trial 1001 (NCT05130255) is a Phase 1 dose-escalation study evaluating the safety and tolerability of GD2-SADA PRIT with Lutetium 177 DOTA in adult and adolescent patients with recurrent or refractory metastatic GD2-expressing solid tumors, including high-risk neuroblastoma. Part A of the trial, which focused on dose escalation, has been completed, and initial data is expected to be released on May 28th during a virtual R&D update.

Analysis

Y-mAbs Therapeutics (YMAB) has announced progress in its clinical development pipeline with the presentation of a trial-in-progress poster for GD2-SADA pretargeted radioimmunotherapy (PRIT) at the Advances in Neuroblastoma Research Meeting. Specifically, Trial 1001 (NCT05130255), a Phase 1, first-in-human, dose-escalation study, is evaluating GD2-SADA PRIT with Lutetium 177 DOTA in adult and adolescent patients (≥ 16 years) suffering from recurrent or refractory metastatic GD2-expressing solid tumors, including high-risk neuroblastoma, small cell lung cancer, sarcoma, and melanoma. A key development is the completion of Part A of this trial, which aimed to define the optimal safe dose of the GD2-SADA protein and evaluate the administration interval. The company has indicated that initial data from Part A will be presented during a virtual Radiopharmaceutical R&D update on May 28th. This upcoming data release is a significant near-term catalyst. The GD2-SADA technology, licensed exclusively from Memorial Sloan Kettering Cancer Center, utilizes a bispecific fusion protein for pre-targeting GD2-positive tumors before delivering a radioactive payload, building on Y-mAbs' focus in radioimmunotherapy and its existing commercial product, DANYELZA®. The announcement carries a moderately positive sentiment (overall score 0.5; YMAB specific 0.7) and an optimistic tone, though the immediate market impact score is relatively low at 0.35, suggesting the market may be awaiting the concrete data from the R&D update.

Key Decisions for Investors

• Investors should closely monitor the initial data readout from Trial 1001 Part A, scheduled for May 28th, as positive safety and dosing findings could de-risk the GD2-SADA PRIT program and serve as a significant valuation catalyst.
• Consider the advancement of the SADA platform as a key component of Y-mAbs' long-term growth strategy, potentially expanding its therapeutic reach beyond its currently approved DANYELZA® into a broader range of GD2-expressing solid tumors.
• Maintain awareness that GD2-SADA PRIT is still in early-stage (Phase 1) clinical development; therefore, while progress is encouraging, investment decisions should factor in the inherent risks and extended timelines associated with oncological drug development.